



**Jubilant Life Sciences Ltd.**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubl.com](http://www.jubl.com)

## **Jubilant Life Sciences receives ANDA approval for Memantine Hydrochloride Tablets**

***Noida (UP), India, Wednesday, October 14, 2015***

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for **Memantine Hydrochloride Tablets USP, 5 mg and 10 mg**, the generic version of Namenda Tablets, 5 mg and 10 mg<sup>®</sup> (of Forest Laboratories), which is used for treatment of moderate to severe dementia in patients with Alzheimer's disease.

As on June 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe.

### **About Jubilant Life Sciences**

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of about 6,000 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

### **For more information please contact:**

#### ***For Investors***

Ravi Agrawal / Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002 / 1021  
E-mail: [ravi\\_agrawal@jubl.com](mailto:ravi_agrawal@jubl.com)  
[anupam\\_jain@jubl.com](mailto:anupam_jain@jubl.com)

Siddharth Rangnekar / Karl Kolah  
Citigate Dewe Rogerson  
Tel: +91 22 6645 1209 / 1220  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[karl@cdr-india.com](mailto:karl@cdr-india.com)

#### ***For Media***

Sudhakar Safaya / Neha Garg  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1034 / 1067  
E-mail: [sudhakar\\_safaya@jubl.com](mailto:sudhakar_safaya@jubl.com)  
[neha\\_garg@jubl.com](mailto:neha_garg@jubl.com)

Kanika Mittal  
Perfect Relations  
Ph: +91 9899574833  
E-mail: [kmittal@perfectrelations.com](mailto:kmittal@perfectrelations.com)



*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*